Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages

  Zarb, P ^a   Amadeo, B ^b   Muller, A ^c   Drapier, N ^c   Vankerckhoven, V ^c   Davey, P ^d   Goossens, H ^c   Metz Gercek, Sigrid ^e   Jansens, Hilde ^e   Markova, Boyka ^e   Kontemeniotou, Christiana ^e   Andrasevic, Arjana ^e   Vlcek, Jiri ^e   Frimodt Møller, Niels ^e   Mitt, Piret ^e   Lyytikainen, Outi ^e   Bertrand, Xavier ^e   de With, Katja ^e   Antoniadou, Anastasia ^e   Ternak, Gabor ^e   Cunney, Robert ^e   Raz, Raul ^e   Brusaferro, Silvio ^e   Dimina, Elina ^e   Butkyte, Vitalija ^e   Marcel, Bruch ^e   Haug, Jon Birger ^e   Pawlowksa, Janina ^e   Teixeira, Ines ^e   Ratchina, Svetlana ^e   Cizman, Milan ^e   Sora, Mercedes ^e   Skoog, Gunilla ^e   Zanetti, Giorgio ^e   Filius, Margreet ^e   Sardan, Yesim Cetinkaya ^e   Cooke, Jonathan ^e   Webb, Hugh ^e   Heginbothom, Margaret ^e   more..

^a MATER DEI HOSPITAL   (Malta)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e NONE

Author keywords

Fluconazole; Hospital antifungal consumption; Hospital acquired infections; Medical prophylaxis; Point prevalence surveys

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CARBAPENEM; CASPOFUNGIN; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; DRUG USE; GASTROINTESTINAL INFECTION; HEALTH SURVEY; HOSPITAL INFECTION; HOSPITALIZATION; INFECTION PREVENTION; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TOTAL QUALITY MANAGEMENT;

FUNGI;

EID: 84866165439     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03973.x     Document Type: Article

References (39)

1. de With K, Steib-Bauert M, Knoth H et al. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 2005; 5: 1.
2. Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60: 619-624.
3. Xie G, Fang X, Fang Q et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Crit Care 2008; 12: R5.
4. Bassetti M, Ansaldi F, Nicolini L et al. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009; 64: 625-629.
5. Sendid B, Cotteau A, François N et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80.
6. Presterl E, Daxböck F, Graninger W, Willinger B. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 2007; 13: 1072-1076.
7. Hajdu A, Samodova OV, Carlsson TR et al. A point prevalence survey of hospital-acquired infections and antimicrobial use in a paediatric hospital in north-western Russia. J Hosp Infect 2007; 66: 378-384.
8. Ceyhan M, Yildirim I, Ecevit C et al. Inappropriate antimicrobial use in Turkish pediatric hospitals: a multicenter point prevalence survey. Int J Infect Dis 2010; 14: e55-e61.
9. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsåker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
10. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 2006; 27 (Suppl 1): 3-6.
11. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai Zasshi 2007; 48: 1-12.
12. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55: 809-818.
13. Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23-30.
14. Poikonen E, Lyytikäinen O, Anttila V, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-990.
15. Gómez J, García-Vázquez E, Espinosa C et al. Nosocomial candidemia at a general hospital: the change of epidemiological and clinical characteristics. A comparative study of 2 cohorts (1993-1998 versus 2002-2005). Rev Iberoam Micol 2009; 26: 184-188.
16. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-494.
17. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
18. Girão E, Levin AS, Basso M et al. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital. Med Mycol 2008; 46: 581-588.
19. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995.
20. San-Juan R, Aguado JM, Lumbreras C et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 2011; 92: 346-350.
21. Sohn HS, Lee T, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther 2009; 31: 1105-1115; discussion 1066-8.
22. Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 2008; 30: 964-973.
23. Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 2012; 55: 2-16.
24. Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 2011; 66 (Suppl 1): i25-i35.
25. Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis 2009; 22: 385-393.
26. Zarb P, Amadeo B, Muller A et al. Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. J Antimicrob Chemother 2011; 66: 443-449.
27. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
28. Schuster MG, Edwards JEJ, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
29. Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 2009; 37: 1580-1593.
30. Faiz S, Neale B, Rios E et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009; 28: 689-692.
31. Lingegowda PB, Tan CK, Tan AL, Tan BH. Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents - a report of two cases. Ann Acad Med Singapore 2011; 40: 287-290.
32. Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother 2010; 65: 769-774.
33. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010; 10: 150.
34. Choi HK, Jeong SJ, Lee HS et al. Blood stream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med 2009; 24: 263-269.
35. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-129.
36. Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy - challenges and future directions. Expert Opin Pharmacother 2005; 6: 2617-2632.
37. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl 3): S318-S326.
38. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56 (Suppl 1): i5-i11.
39. European Centre for Disease Prevention and Control. Annual Report of the Director 2010. http://www.ecdc.europa.eu/en/aboutus/Key%20Documents/1106_COR_Annual_Report_Director_2010.pdf.